Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides a source of calories and hydration. Sodium chloride and potassium chloride replace extracellular fluid and electrolytes.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Fluid and electrolyte replenishment,Correction of hypokalemia,Maintenance of hydration and electrolyte balance,Intravenous infusion for parenteral nutrition (off-label)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous infusion; rate and volume determined by patient's fluid, electrolyte, and caloric requirements; typical adult dose is 1000-2000 m L per 24 hours, infused at a rate of 50-100 m L/hour.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Not applicable as a primary pharmacokinetic parameter for this combination; dextrose follows glucose disposition with a half-life of approximately 1-2 hours in euglycemic individuals, prolonged in diabetes. Electrolytes distribute and are eliminated with functional half-lives reflecting renal handling (e.g., potassium half-life ~6-8 hours).
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Dextrose is metabolized to carbon dioxide and water via glycolysis and the Krebs cycle. Electrolytes are excreted or retained based on renal function.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Dextrose is metabolized to carbon dioxide and water, with negligible renal elimination of unchanged glucose unless hyperglycemia exceeds renal threshold. Sodium and chloride are primarily excreted renally, with >90% of filtered sodium reabsorbed; potassium is predominantly excreted renally (90%) with minor fecal loss (<10%) under normal renal function.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Dextrose: negligible (<1%); sodium: negligible; chloride: negligible; potassium: negligible (<1% bound to albumin).
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Dextrose: approximately 0.2-0.3 L/kg (mainly extracellular fluid); sodium: 0.25 L/kg (extracellular); chloride: 0.25 L/kg; potassium: approximately 0.5 L/kg (distributes into intracellular compartment).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100% (complete bioavailability); not administered via other routes.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
In patients with severe renal impairment (e GFR <30 m L/min/1.73 m²), reduce volume and monitor potassium closely; may require potassium restriction; dosing based on fluid and electrolyte status.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific adjustment for Child-Pugh class A or B; in severe hepatic impairment (Child-Pugh class C), monitor potassium and glucose levels; adjust rate to avoid fluid overload.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Dose based on weight: 100-200 m L/kg per 24 hours for maintenance; adjust for dehydration or electrolyte deficits; typical infusion rate 5-10 m L/kg/hour; maximum rate 15 m L/kg/hour.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Use with caution due to increased risk of fluid and electrolyte imbalances; start at lower end of dosing range; monitor renal function and cardiac status; avoid rapid infusion.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
No FDA black box warning.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Use with caution in patients with renal impairment, heart failure, or edema,Monitor serum electrolytes, glucose, and fluid status,Risk of hyperglycemia, hyperkalemia, or fluid overload,Avoid in patients with intracranial hemorrhage or hemolytic anemia
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hyperkalemia,Hyperglycemia with severe dehydration,Anuria or severe renal failure,Acute intracranial hemorrhage (dextrose-containing solutions),Hypersensitivity to any component
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No known food interactions. However, the potassium content may need to be considered in patients on potassium-restricted diets. Dextrose may affect blood glucose levels; dietary adjustments may be necessary for diabetic patients.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Dextrose, sodium chloride, and potassium chloride are physiological components present in normal body fluids. There is no evidence of teratogenic risk with appropriate use during pregnancy. However, electrolyte imbalances or hyperglycemia from improper administration could pose risks to the fetus. High doses of dextrose in the third trimester may cause fetal hyperinsulinemia and neonatal hypoglycemia. Overall, FDA Pregnancy Category C: risk cannot be ruled out, but use when clearly needed.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Dextrose, sodium chloride, and potassium chloride are normal constituents of human milk and are not expected to cause adverse effects in breastfed infants. M/P ratio: Not applicable as these are endogenous substances. The use of this solution is considered compatible with breastfeeding, provided maternal electrolyte and glucose levels are maintained within normal ranges.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy can alter fluid and electrolyte requirements. Increased plasma volume (up to 50%) and glomerular filtration rate may require higher infusion rates or adjustments to maintain desired electrolyte balance. However, no specific dose adjustment is routinely recommended from standard doses; clinical judgment based on maternal weight, hydration status, and laboratory values should guide therapy.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
This multi-electrolyte solution is commonly used for maintenance and replacement of fluid, electrolytes, and calories. Do not administer simultaneously with blood products due to risk of red cell agglutination and hemolysis. Monitor serum potassium closely in renal impairment. Use with caution in patients with heart failure or edema. Incompatible with amphotericin B, diazepam, and phenytoin.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Do not use this solution if the container is damaged or the solution is cloudy.,Report any signs of infusion site reactions, such as pain, redness, or swelling.,Inform your healthcare provider about all medications you are taking, especially potassium supplements or potassium-sparing diuretics.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Tell your doctor if you have kidney problems, heart disease, or are on a sodium-restricted diet.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides a source of calories and hydration. Sodium chloride and potassium chloride replace extracellular fluid and electrolytes.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by patient's fluid, electrolyte, and caloric requirements; typical adult dose is 1000-2000 m L per 24 hours, infused at a rate of 50-100 m L/hour.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose, sodium chloride, and potassium chloride are physiological components present in normal body fluids. There is no evidence of teratogenic risk with appropriate use during p. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.